The RSVpreF vaccine demonstrated 91% effectiveness against RSV-related lower respiratory tract disease in older adults during ...

Respiratory illness activity is currently considered "high" in the United States, according to the CDC. In one state, it is ...

The 2024 holiday season saw a surge in respiratory virus spread, underscoring the ongoing need for holiday-related virus ...

Vaccines to protect against respiratory syncytial virus (RSV) in newborns and older adults are being more widely ...

The risk of respiratory syncytial virus, or RSV, is on the rise, along with that of other illnesses including the flu, ...

NC was one of 18 states with "high" or "very high" levels in wastewater, according to CDC monitoring. Here's what to know ...

Operations at some pediatric intensive care units are being postponed because of an influx of babies with the respiratory ...

BARS-13 is under clinical development by Beijing Advaccine Biotechnology and currently in Phase II for Respiratory Syncytial Virus (RSV) Infections.

Mask requirements and visitor restrictions have been implemented at OSF HealthCare hospitals to help slow the spread of ...

Johns Hopkins Medicine researchers have shown that people 60 years or older with weakened immunity do not respond as strongly ...

The adjuvanted RSV prefusion F protein-based vaccine RSVPreF3-AS01E Arexvy was first FDA approved for older adults in May ...